Iovance Biotherapeutics Inc. [NASDAQ: IOVA] traded at a low on 01/06/22, posting a -4.58 loss after which it closed the day’ session at $16.05. The company report on January 6, 2022 that Iovance Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that Fred Vogt, PhD, Esq., Interim Chief Executive Officer, President and General Counsel of Iovance, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 7:30 a.m. ET. The live and archived webcasts of the presentation will be available in the Investors section of the Iovance website at http://ir.iovance.com.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
The results of the trading session contributed to over 4811113 shares changing hands. Over the past one week, the price volatility of Iovance Biotherapeutics Inc. stands at 7.97% while the volatility over the past one month is 6.29%.
The market cap for IOVA stock reached $2.53 billion, with 155.51 million shares outstanding and 140.94 million shares in the current float. Compared to the average trading volume of 1.73M shares, IOVA reached a trading volume of 4811113 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Iovance Biotherapeutics Inc. [IOVA]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IOVA shares is $39.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IOVA stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cowen have made an estimate for Iovance Biotherapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on December 07, 2021. The new note on the price target was released on June 10, 2021, representing the official price target for Iovance Biotherapeutics Inc. stock. Previously, the target price had yet another drop from $35 to $18, while Piper Sandler kept a Neutral rating on IOVA stock.
The Average True Range (ATR) for Iovance Biotherapeutics Inc. is set at 1.19 The Price to Book ratio for the last quarter was 3.57, with the Price to Cash per share for the same quarter was set at 3.66.
How has IOVA stock performed recently?
Iovance Biotherapeutics Inc. [IOVA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -17.35. With this latest performance, IOVA shares dropped by -14.54% in over the last four-week period, additionally sinking by -39.73% over the last 6 months – not to mention a drop of -67.24% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IOVA stock in for the last two-week period is set at 28.76, with the RSI for the last a single of trading hit 21.49, and the three-weeks RSI is set at 32.67 for Iovance Biotherapeutics Inc. [IOVA]. The present Moving Average for the last 50 days of trading for this stock 20.13, while it was recorded at 17.91 for the last single week of trading, and 23.87 for the last 200 days.
Iovance Biotherapeutics Inc. [IOVA]: Deeper insight into the fundamentals
Iovance Biotherapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.00 and a Current Ratio set at 9.00.
Insider trade positions for Iovance Biotherapeutics Inc. [IOVA]
There are presently around $2,636 million, in the hands of institutional investors. The top three institutional holders of IOVA stocks are: VANGUARD GROUP INC with ownership of 11,928,989, which is approximately -2.512% of the company’s market cap and around 0.62% of the total institutional ownership; ARK INVESTMENT MANAGEMENT LLC, holding 11,649,837 shares of the stock with an approximate value of $195.95 million in IOVA stocks shares; and PERCEPTIVE ADVISORS LLC, currently with $193.26 million in IOVA stock with ownership of nearly 4.836% of the company’s market capitalization.
122 institutional holders increased their position in Iovance Biotherapeutics Inc. [NASDAQ:IOVA] by around 13,802,343 shares. Additionally, 112 investors decreased positions by around 17,800,823 shares, while 29 investors held positions by with 125,144,363 shares. The mentioned changes placed institutional holdings at 156,747,529 shares, according to the latest SEC report filing. IOVA stock had 33 new institutional investments in for a total of 5,485,375 shares, while 25 institutional investors sold positions of 1,468,038 shares during the same period.